Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.70 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.58 |
| ▸ | NPY2R | P49146 | 3/20 | 0.58 |
| ▸ | NPY4R | P50391 | 3/20 | 0.58 |
| ▸ | ECE1 | P42892 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677508 | 1.00 | GHSR (0.70) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL4677756 | 0.92 | GHSR (0.62) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL4677349 | 0.92 | GHSR (0.62) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL4676288 | 0.91 | GHSR (0.59) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL4678748 | 0.91 | GHSR (0.59) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL4675994 | 0.91 | GHSR (0.80) | GHSRKISS1RECE1 | |
| SCHEMBL4680377 | 0.91 | GHSR (0.80) | GHSRKISS1RECE1 | |
| SCHEMBL4676555 | 0.86 | GHSR (0.59) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL4680471 | 0.86 | GHSR (0.59) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL2183816 | 0.83 | ECE1 (0.64) | GHSRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | GHSR 344/4885KISS1R 1337/4885NPY1R 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.